Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Nasal spray ingredient may offer safer dental pulp treatment for kids

NCT ID NCT07675330

Disease control Sponsor: Cairo University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 30, 2026 · Last updated Jul 01, 2026 · Updated 1 time

Summary

This study tests whether oxymetazoline, a common nasal decongestant, can replace sodium hypochlorite as a bleeding control agent during pulp treatment in children's baby teeth. About 50 Egyptian children aged 4-8 with decayed molars will receive either treatment. The goal is to see if oxymetazoline works as well or better, with fewer side effects.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Oxymetazoline 0.05% nasal solution and Sodium Hypochlorite 5% solution
What this could lead to
If oxymetazoline works as well as sodium hypochlorite, it could offer a safer, less irritating option for stopping bleeding during dental pulp treatment in children.
What could go wrong
This is a small, early-stage trial with only 50 children, so results may not apply broadly. Oxymetazoline is not typically used for this purpose, and its effectiveness compared to the standard treatment is uncertain.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 50 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Aug 2026

An estimate. Start dates often move.

Expected to finish

Dec 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

4 to 8 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: • Patients: Egyptian children with carious mandibular primary molars aged 4-8 years. • Teeth: Restorable mandibular primary molars with no clinical signs or symptoms of irreversible pulpitis. • Pre-operative Radiograph: No radiographic signs of internal or external root resorption and no furcation or periapical radiolucencies. \- Exclusion Criteria: * • Patients: 1. Uncooperative children. 2. Medically compromised children. 3. Patients whose parents refuse to participate or refuse to sign the informed consent. * Teeth: <!-- --> 1. Previously accessed molars. 2. Mobile primary molars. 3. Presence of sinus tract or pain on percussion.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Carious exposure of pulp are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

dental pulp disorder exposure, dental pulp primary failure of tooth eruption pulpitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Carious exposure of pulp Primary molar pulpotomy Primary molar tooth Pulp disease, dental Pulp inflammation Pulp therapy in primary molars Pulpitis - reversible Vital pulp therapies

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Faculty of dentistry, Cairo University.

    Cairo, Egypt

More trials for these conditions

Other studies related to the condition(s) this trial covers.